Methodological considerations on the predictive value of tumor-infiltrating lymphocytes for pathological complete response in early triple-negative breast cancer

Breast Cancer Research and Treatment · Published 2026-08-01 · DOI 10.1007/s10549-026-08048-7

Authors (1)

Malaha Ali

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ali, M. (2026). Methodological considerations on the predictive value of tumor-infiltrating lymphocytes for pathological complete response in early triple-negative breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08048-7

Related articles

• Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen · Breast Cancer Research and Treatment · 2026 · Cites or is cited by this article · Same journal
• Retrospective study on regional nodal irradiation after omission of axillary lymph node dissection in sentinel lymph node-positive breast cancer: a propensity score matching analysis · Breast Cancer Research and Treatment · 2026 · Same journal
• Factors influencing discussion duration in breast cancer multidisciplinary team meetings: insights for streamlining care · Breast Cancer Research and Treatment · 2026 · Same journal
• Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib · Breast Cancer Research and Treatment · 2026 · Same journal
• Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer · Breast Cancer Research and Treatment · 2026 · Same journal
• Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study · Breast Cancer Research and Treatment · 2026 · Same journal
• Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B) · Breast Cancer Research and Treatment · 2026 · Same journal
• Age-stratified difference in patient-reported health-related quality of life following breast cancer surgery · Breast Cancer Research and Treatment · 2026 · Same journal
• Rediscovering the Ciucci pathway: in-vivo evidence of a palmar lymphatic channel · Breast Cancer Research and Treatment · 2026 · Same journal
• Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer · Breast Cancer Research and Treatment · 2026 · Same journal